Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.7K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

23.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

673
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
673

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of Potential Proteins Interacting with α-Galactosidase A to Analyze the Pathogenesis of Fabry Disease.

International journal of molecular sciences·2026
Same author

Loss of lncRNA <i>H19</i> impairs neonatal cardiac regeneration.

American journal of physiology. Cell physiology·2026
Same author

Serotonin 5-HT7 receptor signaling modulates inflammatory responses and survival after myocardial infarction.

Journal of translational medicine·2026
Same author

RNA splicing and cardiovascular disease: a guide for cardiologists.

European heart journal·2026
Same author

The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.

Nature medicine·2026
Same author

Subcutaneous Defibrillator Implantation With or Without Defibrillation Test: The Primary Results of the Randomized PRAETORIAN-DFT Trial.

Circulation·2026

Related Experiment Video

Updated: Jan 5, 2026

Detection of microRNA Expression in Peritoneal Membrane of Rats Using Quantitative Real-time PCR
08:56

Detection of microRNA Expression in Peritoneal Membrane of Rats Using Quantitative Real-time PCR

Published on: June 27, 2017

8.3K

Circulating microRNAs in Fabry Disease.

Ke Xiao1, Dongchao Lu1, Jeannine Hoepfner1

  • 1Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.

Scientific Reports
|October 26, 2019
PubMed
Summary

This study identified circulating microRNAs (miRNAs) in Fabry disease patients. Enzyme replacement therapy (ERT) altered levels of specific miRNAs, suggesting their potential as biomarkers for ERT efficacy.

More Related Videos

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
12:21

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

Published on: November 30, 2013

15.3K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.1K

Related Experiment Videos

Last Updated: Jan 5, 2026

Detection of microRNA Expression in Peritoneal Membrane of Rats Using Quantitative Real-time PCR
08:56

Detection of microRNA Expression in Peritoneal Membrane of Rats Using Quantitative Real-time PCR

Published on: June 27, 2017

8.3K
MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
12:21

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

Published on: November 30, 2013

15.3K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.1K

Area of Science:

  • Biochemistry
  • Genetics
  • Molecular Biology

Background:

  • Fabry disease (FD) is an X-linked genetic disorder caused by alpha-galactosidase A deficiency.
  • Accumulation of globotriaosylceramide leads to multi-organ complications and reduced quality of life.
  • Enzyme replacement therapy (ERT) is a treatment option for FD.

Purpose of the Study:

  • To quantify circulating microRNAs (miRNAs) in Fabry disease patients.
  • To investigate the impact of enzyme replacement therapy (ERT) on circulating miRNA levels.
  • To identify potential miRNA biomarkers for ERT efficacy and patient stratification.

Main Methods:

  • miRNA sequencing using the HTG EdgeSeq System to identify circulating miRNAs.
  • Quantitative real-time PCR (qPCR) to validate differential expression of selected miRNAs.
  • Analysis of serum samples from Fabry disease patients with and without ERT.

Main Results:

  • A total of 296 circulating miRNAs were identified in Fabry disease patients.
  • Six out of nine evaluated miRNAs showed significant differential expression.
  • A distinct miRNA pattern was observed in patients undergoing ERT.

Conclusions:

  • Circulating miRNAs may play a role in the pathophysiology of Fabry disease.
  • Specific miRNA profiles could serve as biomarkers to assess ERT effectiveness.
  • These miRNA markers may aid in identifying Fabry patients who would benefit most from ERT.